



Boaz Cheung

Partner

Locations: **Hong Kong**

Title: **Partner of the Hong Kong office**

Tel: **+852 3916 3393 / +852 3916 3318**

Fax: **+852 3157 0333**

Email: **boazcheung@dehenglaw.com.hk**

Working Language: **Chinese, English**

Practice area: **Capital Markets, Cross-border Investment & Finance**

Boaz's areas of practice cover corporate finance, cross-border mergers and acquisitions and public takeovers. He represented issuers and sponsors in initial public offerings on the Stock Exchange of Hong Kong Limited. Boaz also advises Hong Kong-listed companies on their ongoing compliance obligations under Hong Kong securities legislation and rules.

Representative Matters

- Advising Consun Pharmaceutical Co., Ltd. (Stock Code: 1681) on its initial public offering on the Main Board of the Hong Kong Stock Exchange raising approximately HK\$1 billion (including over-size allotment options).
- Advising Guotai Junan Capital Limited as sole sponsor, in connection with the global offering and IPO of H-shares of Chamracy Pharmaceutical Co., Ltd. (Stock Code: 2289) on the Main Board of the Hong Kong Stock Exchange.
- Advising Guotai Junan Capital Limited as sole sponsor, in connection with the listing of H-shares of Chanjet Information Technology Company Limited on the Main Board of the Hong Kong Stock Exchange. The issuer being a subsidiary of Yonyou Software Co., Ltd. (a company currently listed on the Shanghai Stock Exchange (stock code: 600588)), this project was the first spin off listings of A-share listed companies on the Hong Kong Stock Exchange.
- Advising Guotai Junan Capital Limited as sole sponsor, in connection with the global offering and IPO of H-shares of Holly Futures Co., Ltd (Stock Code: 3678) on the Main Board of the Hong Kong Stock Exchange.
- Advising Ever Harvest Group Holdings Limited (Stock Code: 1549) on its listing on the Main Board of the Stock Exchange.
- Advising WAC Holdings Limited (Stock Code: 8619) on its listing on GEM of the Stock Exchange.
- Advising Oceanwide Holdings Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock Code: 000046) on its acquisition of 71.36% of equity interest in Hutchison Harbour Ring Limited (stock code: 715, "Hutchison Harbour Ring") through its wholly-owned subsidiary, Oceanwide Holdings International Co., Ltd, for a total consideration of HK\$38.2 billion, and the subsequent unconditional mandatory cash offers for all the remaining shares of Hutchison Harbour Ring at a maximum value of approximately HK\$15.3 billion.
- Advising Global Link Communications Holdings Limited (Stock Code: 8060) in responding the unconditional mandatory cash offers made by China Galaxy International Securities (Hong Kong) Co., Limited for and on behalf of Honor Crest Holdings Limited, a wholly-owned subsidiary of International Elite Ltd. (Stock Code: 1328).
- Advising Consun Pharmaceutical Group Limited (Stock code: 1681) on its share repurchase from First Kind Limited, wholly owned subsidiary of Hony Capital Fund III, L.P for a total consideration of HK\$561 million. This transaction constitutes an off-market share buy back under the Takeovers Code.
- Advising NT China NT Pharma Group Company Limited on its issuance of convertible preference shares in the amount of HK\$ 590 million.

Education Background

- Bachelor of Social Sciences (Government and Laws), the University of Hong Kong (2010)
- Bachelor of Laws, the University of Hong Kong (2012)
- Postgraduate Certificate in Laws (PCLL), the University of Hong Kong (2013)

Professional Qualifications

- Solicitor of Hong Kong

Professional Background

- Represents issuers and sponsors in initial public offerings on the Main Board and GEM of the Stock Exchange of Hong Kong Limited
- Represents issuers in secondary issues by way of placing of share, rights issue and subscription of shares and/or convertible securities.
- Mergers acquisitions, corporate restructuring, and main board and GEM listed issuers in respect of the compliance with Listing Rules and Takeovers Code.

Selected Publications

- ALB Hong Kong IPO Handbook 2021 (Chapter 4: IPO application process)